Natera (NASDAQ:NTRA) Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Natera (NASDAQ:NTRA) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

NTRA has been the topic of several other reports. Piper Jaffray Companies set a $40.00 price target on shares of Tapestry and gave the company a buy rating in a report on Monday, June 10th. BidaskClub cut shares of Virtu Financial from a sell rating to a strong sell rating in a report on Wednesday, June 12th. Finally, Canaccord Genuity reaffirmed an average rating on shares of Kellogg in a report on Tuesday, June 25th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $30.14.

NTRA opened at $25.64 on Wednesday. The company has a fifty day moving average of $24.89. The company has a debt-to-equity ratio of 20.88, a quick ratio of 1.73 and a current ratio of 1.85. Natera has a 12-month low of $11.08 and a 12-month high of $29.62.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.05. The firm had revenue of $66.82 million for the quarter, compared to analysts’ expectations of $66.40 million. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. As a group, equities research analysts anticipate that Natera will post -2.17 EPS for the current fiscal year.

In other Natera news, Chairman Matthew Rabinowitz sold 1,418 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $35,152.22. Following the completion of the sale, the chairman now owns 1,286,612 shares in the company, valued at $31,895,111.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 1,033 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $25,608.07. Following the sale, the insider now owns 240,061 shares of the company’s stock, valued at approximately $5,951,112.19. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,771 shares of company stock valued at $140,742. 9.29% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new stake in Natera during the first quarter valued at $264,000. MYDA Advisors LLC bought a new stake in Natera during the first quarter valued at $722,000. AGF Investments Inc. bought a new stake in Natera during the first quarter valued at $1,031,000. NumerixS Investment Technologies Inc increased its stake in Natera by 86.5% during the first quarter. NumerixS Investment Technologies Inc now owns 13,616 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 6,316 shares during the last quarter. Finally, Asymmetry Capital Management L.P. bought a new stake in Natera during the first quarter valued at $628,000. Hedge funds and other institutional investors own 80.27% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Article: Trade Deficit

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.